Skip to main content

Table 1 Clinicopathologic characteristics according to KRAS mutation status

From: The prognostic significance of KRAS and BRAF mutation status in Korean colorectal cancer patients

  Patients with KRAS status p-value
Negative Positive Total
(N = 691) (N = 401) (N = 1092)
Sex     0.001
 Male 452 (65.4%) 220 (54.9%) 672 (61.5%)  
 Female 239 (34.6%) 181 (45.1%) 420 (38.5%)  
Age     0.771
  < 50 year 90 (13.0%) 49 (12.2%) 139 (12.7%)  
  ≥ 50 year 601 (87.0%) 352 (87.8%) 953 (87.3%)  
Location     <0.001
 Rt colon 145 (21.0%) 130 (32.4%) 275 (25.2%)  
 Lt colon 309 (44.7%) 158 (39.4%) 467 (42.8%)  
 Rectum 221 (32.0%) 107 (26.7%) 328 (30.0%)  
 Multiple 16 (2.3%) 6 (1.5%) 22 (2.0%)  
Stage     0.889
 Tis 15 (2.2%) 8 (2.0%) 23 (2.1%)  
 StageI 129 (18.8%) 75 (18.8%) 204 (18.8%)  
 StageII 195 (28.3%) 112 (28.0%) 307 (28.2%)  
 StageIII 256 (37.2%) 142 (35.5%) 398 (36.6%)  
 StageIV 93 (13.5%) 63 (15.8%) 156 (14.3%)  
T stage     0.005
 T1 71 (10.5%) 25 (6.4%) 96 (9.0%)  
 T2 100 (14.8%) 77 (19.7%) 177 (16.6%)  
 T3 429 (63.6%) 229 (58.6%) 658 (61.8%)  
 T4 74 (11.0%) 60 (15.3%) 134 (12.6%)  
N stage     0.897
 N0 362 (52.5%) 207 (51.6%) 569 (52.2%)  
 N1 184 (26.7%) 106 (26.4%) 290 (26.6%)  
 N2 143 (20.8%) 88 (21.9%) 231 (21.2%)  
M stage     0.35
 M0 598 (86.5%) 338 (84.3%) 936 (85.7%)  
 M1 93 (13.5%) 63 (15.7%) 156 (14.3%)  
Lymphatic invasion     0.163
 Absent 392 (56.8%) 209 (52.2%) 601 (55.1%)  
 Present 298 (43.2%) 191 (47.8%) 489 (44.9%)  
Venous invasion     0.055
 Absent 558 (81.0%) 343 (85.8%) 901 (82.7%)  
 Present 131 (19.0%) 57 (14.2%) 188 (17.3%)  
Perineural invasion     0.123
 Absent 537 (77.8%) 294 (73.5%) 831 (76.2%)  
 Present 153 (22.2%) 106 (26.5%) 259 (23.8%)  
Differentiation     0.002
 Well/Moderate 629 (94.7%) 374 (98.7%) 1003 (96.2%)  
 Poor 35 (5.3%) 5 (1.3%) 40 (3.8%)  
Histology     0.008
 Non-mucinous adenocarcinoma 657 (95.1%) 364 (90.8%) 1021 (93.5%)  
 Mucinous adenocarcinoma 34 (4.9%) 37 (9.2%) 71 (6.5%)  
Recur     0.143
 Recur 593 (85.8%) 330 (82.3%) 923 (84.5%)  
 Non-recur 98 (14.2%) 71 (17.7%) 169 (15.5%)  
Expire     0.219
 Expire 629 (91.0%) 355 (88.5%) 984 (90.1%)  
 Non- Expire 62 (9.0%) 46 (11.5%) 108 (9.9%)  
Neoadjuvant Tx     0.217
 No 605 (87.6%) 364 (90.8%) 969 (88.7%)  
 CTx 31 (4.5%) 10 (2.5%) 41 (3.8%)  
 RT 2 (0.3%) 0 (0.0%) 2 (0.2%)  
 CCRT 53 (7.7%) 27 (6.7%) 80 (7.3%)